World Library  
Flag as Inappropriate
Email this Article
 

Andrew von Eschenbach

Andrew C. von Eschenbach (born October 30, 1941 in Philadelphia, Pennsylvania) was the Commissioner of the United States Food and Drug Administration from 2006–2009. He became acting Commissioner on September 26, 2005, after the resignation of his predecessor Lester Crawford, and was confirmed as Commissioner by the Senate on December 7, 2006.[1][2] He was previously the 12th director of the National Cancer Institute.

Von Eschenbach currently serves on the Board of Directors of BioTime (NYSE MKT: BTX), a biotechnology company helmed by CEO Michael D. West, PhD.[3] He also serves as a director of Viamet Pharmaceuticals. [4]

Contents

  • Biography 1
  • Notes 2
  • References 3
  • See also 4
  • External links 5

Biography

After graduating from Pennsylvania Hospital in general surgery and urology and taught urology at the University of Pennsylvania School of Medicine. He served in the US Navy Medical Corps with the rank of lieutenant commander from 1968 to 1971.

In 1976, von Eschenbach began his long association with The University of Texas M. D. Anderson Cancer Center, beginning as a urologic oncology fellow and becoming chair of the department of urology in 1983. He was founding director of the Prostate Cancer Research Program in 1996, director of the Genitourinary Cancer Center, and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology. Driven by his father's prostate cancer, he specialized in the disease.

Von Eschenbach was president-elect of the Provenge for the treatment of late stage prostate cancer against the recommendation of an independent advisory committee.

Von Eschenbach was criticized for overruling his staff recommendations, and approving the Menaflex knee implant, made by ReGen Biologics Inc., New Jersey, on a fast-track basis, after four New Jersey congressmen lobbied on ReGen's behalf. Von Eschenbach said, "We fumbled that process."[5]

In 2006, Time named him as one of the Time 100 "People Who Shape Our World", writing that as head of the FDA, which "wields enormous influence on American lives", von Eschenbach "could make a signal contribution to the public's health" by focusing on issues of diet and obesity in addition to drugs and disease.

On August 1, 2006, Senators Clinton and Cantwell announced they would block his nomination to be the permanent FDA commissioner because of his department's failure to act on the application by Barr Pharmaceuticals to sell Plan B over-the-counter. They ultimately voted for his nomination.[2]

Andrew von Eschenbach was instrumental in the development and growth of the Prostate Cancer Foundation (founded by Michael Milken) since its inception in 1993 and held a board membership position and scientific advisor role at the foundation. C-Change, a forum that brings together the principal leaders of key national cancer organizations, and founded by Andrew von Eschenbach, is in partnership with the Prostate Cancer Foundation.

Notes

  1. ^ U.S. Congress (7 December 2006). "Executive Session". Congressional Record 152 (134): S11404–29, S11447–51. Retrieved 2006-12-12. 
  2. ^ a b Senate Vote No. 274
  3. ^ "BioTime, Inc. Appoints Andrew C. von Eschenbach, M.D. to its Board of Directors". BusinessWire Press Release. November 9, 2011. 
  4. ^ Viamet Pharmaceuticals web site 
  5. ^ Political Lobbying Drove FDA Process, by Alicia Mundy, Wall Street Journal, March 6, 2009

References

  • "Andrew von Eschenbach." Biography Resource Center Online. Gale, 2006.

See also

External links

  • Food and Drug Administration biography
  • National Cancer Institute biography
  • "Biosketch for Dr. Andrew von Eschenbach", NCI BenchMarks, vol. 2 no. 1, January 22, 2002.
  • BioTime web site
  • "Andrew von Eschenbach: Entering the Fray at the FDA", Michael Jacobson, Time, April 30, 2006.
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.